Quick Facts: Therapeutic Domains

• Adjuvant Treatment: Management of hormone receptor-positive early breast cancer in postmenopausal women.
• Extended Adjuvant Treatment: Use following a standard course of tamoxifen therapy in postmenopausal women with early breast cancer.
• Advanced Disease Management: Primary or secondary intervention for hormone receptor-positive advanced or metastatic breast cancer in postmenopausal patients.

---

Letrozole Actavis is a prescription medication utilized in oncology for the comprehensive management of breast cancer in women who have reached menopause. The medication is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer following initial surgery. It is also approved for extended adjuvant treatment for patients who have completed a prior five-year course of standard adjuvant therapy, such as tamoxifen, to help in sustained management.

Furthermore, Letrozole Actavis is used for the first-line treatment of advanced breast cancer that is either hormone receptor-positive or of unknown status, including locally advanced or metastatic disease. It is also an option for treating advanced breast cancer in patients who experience disease progression after having received prior anti-estrogen therapy.

The eligibility for Letrozole Actavis is strictly defined by regulatory authorities based on hormonal status, age, organ function, and specific conditions.

Contraindicated Populations

Use is absolutely prohibited (contraindicated) for the following groups:

• Women of premenopausal endocrine status.
• Women who are pregnant or breast-feeding.
• Patients with a known hypersensitivity to letrozole or any excipients.

Age and Organ Function Eligibility

Category	Regulatory Status
Pediatric (Under 18)	Not recommended; safety and efficacy have not been established (Source 2.5).
Geriatric (65+)	Eligible; no dose adjustment is required (Source 2.5).
Severe Hepatic Impairment	Requires close supervision; a dose reduction is recommended (Source 1.6).
Severe Renal Impairment (CCr < 10 mL/min)	Insufficient data; risk/benefit must be carefully considered (Source 2.6).

Eligibility-Context Constraints

The medicine is limited to postmenopausal women (Source 2.5). Use in women of child-bearing potential is contingent on a clearly established postmenopausal status, and adequate contraception must be discussed if pregnancy is a possibility (Source 1.6). Furthermore, patients with a history of osteoporosis require formal Bone Mineral Density (BMD) monitoring prior to and during therapy (Source 2.6).

Interactions with other medicines and products

Official regulatory documentation outlines specific interaction patterns for Letrozole that center on hormonal antagonism and metabolic enzyme activity.

---

Documented Interaction Restrictions

Co-administration with oestrogen-containing therapies (such as hormone replacement therapy) and other anti-oestrogens (including Tamoxifen) should be avoided. These substances exhibit pharmacodynamic antagonism and are officially documented to substantially decrease Letrozole plasma concentrations (e.g., by approximately 38% with Tamoxifen), diminishing its pharmacological action.

Metabolic Enzyme-Mediated Interactions

Letrozole's clearance is affected by medicines and substances that modify the Cytochrome P450 (CYP) enzyme system.

• Increased Exposure: Strong inhibitors of CYP3A4 and CYP2A6 (e.g., ketoconazole, ritonavir) can decrease the metabolism of Letrozole, resulting in increased systemic exposure.
• Decreased Exposure: Strong inducers of CYP3A4 (e.g., rifampicin, phenytoin) can increase Letrozole's metabolism, leading to decreased plasma concentrations. The herbal product St. John's Wort is also documented as a CYP3A4 inducer that may reduce exposure.

Population-Specific Notes

In patients with severe hepatic impairment (Child-Pugh C), reduced physiological clearance is officially documented to approximately double the systemic exposure (AUC and terminal half-life) of Letrozole compared to healthy individuals.

Letrozole Actavis operates through a highly targeted biological mechanism centered on achieving significant estrogen suppression. Its action is classified within the domain of enzyme inhibition, leading to a specific physiological cascade that results in the intended modulation of the endocrine system.

Targeted Aromatase Enzyme Inhibition

This mechanism focuses on the Aromatase Enzyme (CYP19A1), the specific molecular target responsible for synthesizing estrogens. Letrozole is a competitive, reversible inhibitor that binds to the enzyme's active site, effectively halting the conversion of precursor androgen hormones into active estradiol (E2) and estrone (E1). This action modulates key pathways associated with steroid hormone metabolism, initiating the process of estrogen reduction.

Substantial Extragonadal Estrogen Suppression

The immediate result of enzyme inhibition is the blockade of the extragonadal (peripheral) estrogen biosynthesis pathway. In the relevant physiological context (postmenopause), this peripheral production is the body's main source of estrogen. The mechanism achieves a substantial systemic reduction of circulating estrogen concentrations. This biological suppression creates a state of hormonal deficiency, leading to the inhibition of estrogen-driven cellular proliferation.

How to Use Letrozole Actavis: Official Administration Guidelines

Letrozole Actavis is administered as a 2.5 mg film-coated tablet taken orally. This is the established strength and route of administration for the medication. The standard regimen for all approved uses in adult postmenopausal women is 2.5 mg once daily.

---

Administration Timing and Special Conditions

Instruction Category	Official Guideline
Dosing Frequency	Once daily
Food Relationship	May be taken with or without food
Elderly Patients	No dose adjustment is required for patients 65 years of age or older
Renal Impairment	No dose adjustment is required for patients with mild to moderate kidney issues (CLcr 10 mL/min)
Severe Hepatic Impairment	The dose is modified to 2.5 mg every other day

---

Treatment Duration and Missed Doses

Treatment duration is determined by the specific condition being managed. For adjuvant therapy, the medicine is typically taken for 5 years, whereas treatment for advanced disease is continued until the tumor shows progression.

If a daily dose is missed, it should be taken as soon as the patient remembers, unless it is close to the time of the next scheduled dose (e.g., within 2 to 3 hours). If the next dose is due shortly, the missed dose is skipped, and the regular schedule is resumed. A double dose must not be taken to compensate for a missed dose. The consistent protocol of 2.5 mg once daily is the standard administration protocol.

Research Evidence / Overview of Studies for Letrozole Actavis

This section outlines the structure of the clinical research conducted for the medicine, describing the types of studies, the outcomes measured, and the areas where data remains limited. The findings describe patterns observed in large groups, not individual patient predictions.

---

Evidence for Initial Adjuvant Treatment of Early Breast Cancer

Research for this use relies primarily on large-scale, international Randomized Controlled Trials (RCTs) involving postmenopausal women with hormone receptor-positive early breast cancer. These studies were designed to compare the use of the medicine against other hormonal therapies. Key long-term outcomes monitored included Disease-Free Survival (DFS), which tracks the time until cancer recurrence, and Overall Survival (OS).

Major trial reports describe patterns related to recurrence rates and distant metastasis measurements in the studied populations. While extensive data exist for the primary group, results apply primarily to the populations studied. The interpretation of very long-term overall survival findings is often complicated by patients receiving subsequent, varying treatments outside the study protocol.

Evidence for Extended Adjuvant Treatment

Studies exploring the extended use of this medicine were conducted using Randomized, Placebo-Controlled Trials. These included postmenopausal women who had been disease-free after completing an initial course of prior hormonal therapy. The research explored outcomes, with studies monitoring DFS and the incidence of Contralateral Breast Cancer (cancer in the opposite breast) over the extension period.

Trial reports described the recurrence rates observed in the study group and those observed in the group receiving a placebo. The evidence quality varies across studies regarding the specific optimal duration for extended therapy. Long-term effects for all potential health outcomes are continually monitored in ongoing research.

Evidence for Advanced or Metastatic Disease Management

Research for locally advanced or metastatic hormone receptor-positive disease involved Randomized Phase III Trials. These compared the medicine against older hormonal agents or in combination with newer targeted therapies. Outcomes monitored included the time before disease worsened, Progression-Free Survival (PFS), and Objective Response Rate (ORR), which measures tumor shrinkage. Comparative evidence is often limited regarding the optimal combination strategy in patients who have received multiple prior treatments.

Common questions about Letrozole Actavis (FAQ)

---

Q: What is Letrozole Actavis?

Letrozole Actavis is a medicine used to treat hormone-dependent breast cancer in women after menopause. It belongs to a group of medicines called aromatase inhibitors. It works by reducing the amount of estrogen your body makes, which can help slow or stop the growth of breast cancer cells that need estrogen to grow.

---

Q: How should I take Letrozole Actavis?

The usual dose is one tablet (2.5 mg) once a day. You should take the tablet whole with a glass of water, with or without food, at about the same time each day. Follow your doctor's instructions exactly and do not stop taking the medicine unless your doctor tells you to. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

---

Q: What are the common side effects of Letrozole Actavis?

Like all medicines, Letrozole Actavis can cause side effects, although not everybody gets them. Hot flashes are one of the most common side effects. Other common side effects may include:

• Fatigue (feeling tired or weak)
• Joint pain (arthralgia) or muscle pain
• Headache
• Nausea
• Increased sweating (hyperhidrosis)
• Dizziness
• Hair thinning
• Weight gain

If you experience any concerning side effects, you should talk to your doctor or pharmacist.

---

Q: Can Letrozole Actavis affect my bones?

Yes, Letrozole Actavis can sometimes lead to a decrease in bone mineral density, which may increase the risk of developing osteoporosis (thinning of the bones) and fractures. This is because the medicine lowers estrogen levels in the body, and estrogen helps maintain bone strength. Your doctor may monitor your bone health, perhaps with a bone density scan (DEXA scan), and may recommend taking calcium and Vitamin D supplements to help protect your bones.

---

Q: How long will I need to take Letrozole Actavis?

The length of treatment varies depending on your individual situation and your doctor's assessment. It is typically a long-term treatment that can last for several years. You must continue taking the tablets every day for as long as your doctor prescribes, even if you feel well. Do not stop treatment without discussing it with your doctor first.

Official Storage and Disposal Requirements

Official regulatory documents define strict storage and disposal requirements for Letrozole Actavis.

Storage Conditions

The tablets must be stored below 30 C and protected from moisture. The medicine must be kept in its original packaging until it is time to take them, as this helps to maintain the product's stability. Patients must avoid storing the tablets in areas of high heat or dampness, such as bathrooms, cars, or near windowsills, and the tablets must not be frozen.

Child Safety

Letrozole Actavis must be kept strictly out of the sight and reach of children. Regulatory guidance advises storing the medicine in a secure location, such as a locked cupboard placed at least 1.5 meters above the ground.

Disposal Instructions

Disposal must adhere to official guidelines. Patients are instructed not to throw away any unused or expired medicines via wastewater or household waste. Instead, patients must consult a pharmacist for guidance on how to properly discard the tablets, ensuring proper handling of pharmaceutical waste and protection of the environment.